[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
Salute e medicinaOne-Off3aManifold MarketsSenza KYCDati di risoluzione verificatiDiscretamente calibratoPrevisione della comunità attuale2030 36.4%In testa tra 6 esiti
Previsori
21
Tipo di domanda
multiple choice
Metodologia
Play-money forecasting platform
Tipo di fonte
Previsione
Variazione 7g
0.0 pts
Dati di mercato
Aggiornato 10 ore fa
Obsoleto18 nov 23, 22:14 UTC1 gen 30, 04:59 UTC
Trend
Regole
Inspired by https://manifold.markets/AaronKaufman/will-any-fdaapproved-glp1-agonists and will use the same criteria:
- GLP-1 agonists, such as semaglutide (ozempic/wegovy), tirzepatide (mounjaro), and dulaglutide (Trulicity), are becoming popular for weight loss and Type-2 diabetes treatment.
- This market resolves positively if any approved GLP-1 agonists for either T2D or weight loss are withdrawn from the market due to safety reasons by the listed date.
- This applies either if the FDA mandates it or if the company withdraws the drug voluntarily.
